Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Berzosertib + Cisplatin + Veliparib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Berzosertib | VX-970|VE-822|M6620 | ATR Inhibitor 16 | Berzosertib (VX-970) is a small molecule inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents resulting in antitumor activity (PMID: 25269479, PMID: 32109490). | |
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Veliparib | ABT-888 | PARP Inhibitor (Pan) 31 | Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02723864 | Phase I | Berzosertib + Cisplatin + Veliparib | Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors | Completed | USA | 0 |